Eye Drops: FDA Statement - Potential Risk of Loose Safety Seals
A loose safety seal or ring presents a safety risk as it may cause eye injuries.
Italiano
A loose safety seal or ring presents a safety risk as it may cause eye injuries.
EUROmediCAT – “Safety of medication use in pregnancy”, a project of the Seventh Framework Programme for Research and Technical Development funded by the European Union in the period 2011-2015, experimented integrating “traditional” registers for congenital anomalies with other already existing healthcare databases to develop and evaluate a surveillance system on the safety of medications during pregnancy. Nine European partners participated to the projects, among which, as Italian partner, the Institute of Clinic Physiology of the CNR, Pisa.1
FDA reviewed updated reprocessing instructions and validation data; FDA recommends that facilities implement them as soon as possible.
L'Agenzia europea per i medicinali (EMA), su richiesta della Commissione europea, ha iniziato la revisione di un medicinale anti-cancro Zydelig (idelalisib), autorizzato nell'UE per il trattamento di due tipi di tumori rari del sangue denominati leucemia linfocitica cronica e linfoma follicolare (uno del gruppo di tumori chiamati linfomi non-Hodgkin).
L'Agenzia Italiana del Farmaco rende disponibili nuovi e importanti aggiornamenti sulle misure di minimizzazione del rischio di PML con l’uso del medicinale Tysabri (natalizumab).
If the separation occurs, patient may bleed from the sheath. If bleeding is not promptly addressed, significant blood loss/exsanguination, interruption/loss of intra-aortic balloon pump treatment may occur.
Administration of a glass particulate may result in local irritation, swelling, and blockage or clotting in blood vessels, which may be life-threatening if a critical organ is affected.
Administration of a non-sterile product intended to be sterile may result in serious and potentially life threatening infections or death.
80.211.154.110